DNA-daunorubicin complexes specifically suppress in vitro spontaneous anti-DNA antibody production in lymphocytes of patients with systemic lupus erythematosus

Tsutomu Takeuchi, J. Koide, O. Hosono, K. Amano, M. Homma, Y. Masuho, C. Morimoto, M. Takano, T. Abe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Elevated production of anti-DNA antibody in patients with systemic lupus erythematosus (SLE) is a central problem in the pathogenesis of tissue injury. In the present study, we attempted to manipulate anti-DNA antibody production through the antigen-cytotoxic drug conjugates, DNA-daunorubicin complexes. The effect of DNA-daunorubicin complexes was determined by examining SLE lymphocytes for spontaneous in vitro production of anti-DNA antibody. These complexes, at 2 μg/ml, suppressed anti-DNA antibody production, but not total IgG production, which suggests that specific suppression of anti-DNA antibody production was achieved at this concentration. We believe that the DNA-daunorubicin complexes affected mainly B cells, since such suppression was obtained by treating B cells, as well as B plus T cells. Furthermore, the complexes had no effect on the proliferative responses of SLE T cells to DNA, phytohemagglutinin, or concanavalin A. These results indicate that DNA-daunorubicin complexes may have the potential for selectively suppressing anti-DNA antibody production in patients with SLE.

Original languageEnglish
Pages (from-to)1216-1222
Number of pages7
JournalArthritis and Rheumatism
Volume29
Issue number10
Publication statusPublished - 1986

Fingerprint

Antinuclear Antibodies
Systemic Lupus Erythematosus
Antibody Formation
Lymphocytes
B-Lymphocytes
T-Lymphocytes
Phytohemagglutinins
Concanavalin A
In Vitro Techniques
daunorubicin-DNA
Immunoglobulin G
Antigens
DNA
Wounds and Injuries
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

DNA-daunorubicin complexes specifically suppress in vitro spontaneous anti-DNA antibody production in lymphocytes of patients with systemic lupus erythematosus. / Takeuchi, Tsutomu; Koide, J.; Hosono, O.; Amano, K.; Homma, M.; Masuho, Y.; Morimoto, C.; Takano, M.; Abe, T.

In: Arthritis and Rheumatism, Vol. 29, No. 10, 1986, p. 1216-1222.

Research output: Contribution to journalArticle

Takeuchi, Tsutomu ; Koide, J. ; Hosono, O. ; Amano, K. ; Homma, M. ; Masuho, Y. ; Morimoto, C. ; Takano, M. ; Abe, T. / DNA-daunorubicin complexes specifically suppress in vitro spontaneous anti-DNA antibody production in lymphocytes of patients with systemic lupus erythematosus. In: Arthritis and Rheumatism. 1986 ; Vol. 29, No. 10. pp. 1216-1222.
@article{b954a77b2d904c77ac79695a55dc1767,
title = "DNA-daunorubicin complexes specifically suppress in vitro spontaneous anti-DNA antibody production in lymphocytes of patients with systemic lupus erythematosus",
abstract = "Elevated production of anti-DNA antibody in patients with systemic lupus erythematosus (SLE) is a central problem in the pathogenesis of tissue injury. In the present study, we attempted to manipulate anti-DNA antibody production through the antigen-cytotoxic drug conjugates, DNA-daunorubicin complexes. The effect of DNA-daunorubicin complexes was determined by examining SLE lymphocytes for spontaneous in vitro production of anti-DNA antibody. These complexes, at 2 μg/ml, suppressed anti-DNA antibody production, but not total IgG production, which suggests that specific suppression of anti-DNA antibody production was achieved at this concentration. We believe that the DNA-daunorubicin complexes affected mainly B cells, since such suppression was obtained by treating B cells, as well as B plus T cells. Furthermore, the complexes had no effect on the proliferative responses of SLE T cells to DNA, phytohemagglutinin, or concanavalin A. These results indicate that DNA-daunorubicin complexes may have the potential for selectively suppressing anti-DNA antibody production in patients with SLE.",
author = "Tsutomu Takeuchi and J. Koide and O. Hosono and K. Amano and M. Homma and Y. Masuho and C. Morimoto and M. Takano and T. Abe",
year = "1986",
language = "English",
volume = "29",
pages = "1216--1222",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - DNA-daunorubicin complexes specifically suppress in vitro spontaneous anti-DNA antibody production in lymphocytes of patients with systemic lupus erythematosus

AU - Takeuchi, Tsutomu

AU - Koide, J.

AU - Hosono, O.

AU - Amano, K.

AU - Homma, M.

AU - Masuho, Y.

AU - Morimoto, C.

AU - Takano, M.

AU - Abe, T.

PY - 1986

Y1 - 1986

N2 - Elevated production of anti-DNA antibody in patients with systemic lupus erythematosus (SLE) is a central problem in the pathogenesis of tissue injury. In the present study, we attempted to manipulate anti-DNA antibody production through the antigen-cytotoxic drug conjugates, DNA-daunorubicin complexes. The effect of DNA-daunorubicin complexes was determined by examining SLE lymphocytes for spontaneous in vitro production of anti-DNA antibody. These complexes, at 2 μg/ml, suppressed anti-DNA antibody production, but not total IgG production, which suggests that specific suppression of anti-DNA antibody production was achieved at this concentration. We believe that the DNA-daunorubicin complexes affected mainly B cells, since such suppression was obtained by treating B cells, as well as B plus T cells. Furthermore, the complexes had no effect on the proliferative responses of SLE T cells to DNA, phytohemagglutinin, or concanavalin A. These results indicate that DNA-daunorubicin complexes may have the potential for selectively suppressing anti-DNA antibody production in patients with SLE.

AB - Elevated production of anti-DNA antibody in patients with systemic lupus erythematosus (SLE) is a central problem in the pathogenesis of tissue injury. In the present study, we attempted to manipulate anti-DNA antibody production through the antigen-cytotoxic drug conjugates, DNA-daunorubicin complexes. The effect of DNA-daunorubicin complexes was determined by examining SLE lymphocytes for spontaneous in vitro production of anti-DNA antibody. These complexes, at 2 μg/ml, suppressed anti-DNA antibody production, but not total IgG production, which suggests that specific suppression of anti-DNA antibody production was achieved at this concentration. We believe that the DNA-daunorubicin complexes affected mainly B cells, since such suppression was obtained by treating B cells, as well as B plus T cells. Furthermore, the complexes had no effect on the proliferative responses of SLE T cells to DNA, phytohemagglutinin, or concanavalin A. These results indicate that DNA-daunorubicin complexes may have the potential for selectively suppressing anti-DNA antibody production in patients with SLE.

UR - http://www.scopus.com/inward/record.url?scp=0022467357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022467357&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 1216

EP - 1222

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 10

ER -